Evidence map›Paper›PMID 38223932›Full record

ReviewAmerican journal of physiology. Cell physiology2024

Permissive role of vascular endothelium in fibrosis: focus on the kidney.

Michael S Goligorsky

Open access · greenAbstract readReview
In one paragraph

Review in American journal of physiology. Cell physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Integrating Senescence and Oxidative Stress in Cardiac Disease.International journal of molecular sciences · 2025
    Review
  10. Targeting long non-coding RNAMolecular therapy. Nucleic acids · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Michael S GoligorskyDepartment of Medicine, New York Medical College, Touro University, Valhalla, New York, United States.ORCID 0000-0003-0561-4469
New York Medical College · US

Funding

Glycocalyx repair in sepsis using liposomal carriers of preassembled glycocalyxR01HL144528 · NHLBI · NEW YORK MEDICAL COLLEGE · PI GOLIGORSKY, MICHAEL S, SUN, DONG · 2019 to 2022
$2.2M
National Institute of Health USA HL144528NHLBI NIH HHS R01 HL144528
6 · The paper itself

Abstract

Fibrosis, the morphologic end-result of a plethora of chronic conditions and the scorch for organ function, has been thoroughly investigated. One aspect of its development and progression, namely the permissive role of vascular endothelium, has been overshadowed by studies into (myo)fibroblasts and TGF-β; thus, it is the subject of the present review. It has been established that tensile forces of the extracellular matrix acting on cells are a prerequisite for mechanochemical coupling, leading to liberation of TGF-β and formation of myofibroblasts. Increased tensile forces are prompted by elevated vascular permeability in response to diverse stressors, resulting in the exudation of fibronectin, fibrinogen/fibrin, and other proteins, all stiffening the extracellular matrix. These processes lead to the development of endothelial cells dysfunction, endothelial-to-mesenchymal transition, premature senescence of endothelial cells, perturbation of blood flow, and gradual obliteration of microvasculature, leaving behind "string" vessels. The resulting microvascular rarefaction is not only a constant companion of fibrosis but also an adjunct mechanism of its progression. The deepening knowledge of the above chain of pathogenetic events involving endothelial cells, namely increased permeability-stiffening of the matrix-endothelial dysfunction-microvascular rarefaction-tissue fibrosis, may provide a roadmap for therapeutic interventions deemed to curtail and reverse fibrosis.

Indexed as

Endothelium, VascularMicrovascular RarefactionEndothelial CellsFibrosisHumansKidneyTransforming Growth Factor betaTransforming Growth Factor betaendothelial cell dysfunctionendothelial-mesenchymal transitionextracellular matrixpremature cell senescencevascular permeability

Identifiers

PMID38223932
PMCPMC11193458
OpenAlexW4390885152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.